This is evident when it is reported from a meta-analysis of randomized control trials that anti-TNF therapy is associated with a significantly increased risk of developing hypertension in patients with rheumatoid arthritis.33 This trial renders a caution that the physicians should be aware of this risk and provide continuing monitoring in patients receiving these therapies. The gene discussed is TNF; the disease is hypertensive disorder.